Opto | Genome editing

Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 68% of retail investor accounts lose money when spread betting and/or trading CFDs with this provider. You should consider whether you understand how spread bets, CFDs, OTC options or any of our other products work and whether you can afford to take the high risk of losing your money.

68% of retail investor accounts lose money when spread betting and/or trading CFDs with this provider. You should consider whether you can afford to take the high risk of losing your money.

Genome editing

Genome editing is the manipulation of DNA in the genome of a living organism. The theme has shot to prominence in the wake of COVID-19, with the excitement surrounding the potential testing applications of CRISPR technology. ETFs in this space give investors exposure to Bioinformatics, Targeted Therapeutics & Molecular Diagnostics.

Show details

LiveClosed Updated: Refresh

Past performance is not a reliable indicator of future results. All themes

VRTX Stock: Why Did ARK Sell This Biotech?

Industry spotlight
Genomics
Immunology
Biotechnology
Health & wellness

VRTX Stock: Why Did ARK Sell This Biotech?

The Vertex share price has enjoyed a healthy rise this year thanks to its dominance in the cystic fibrosis drug market, although this might come to be challenged. Bringing treatments to the market for other conditions and diseases will likely be key to VRTX stock’s future success.

07 Aug 2024